ReviewTouchREVIEWS in endocrinology2022
Statin-related Muscle Toxicity: An Evidence-based Review.
Review in TouchREVIEWS in endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Atorvastatin-Associated Severe Bradyarrhythmia Following Multiorgan Dysfunction: A Case Report.Clinical case reports · 2026Article
- Korean red ginseng extract ameliorates high-fat diet-induced hyperlipidemia by modulating the gut microbiota-liver metabolic axis.Journal of ginseng research · 2026Article
- Reengineering statin therapy to protect skeletal muscle: nanocarrier strategies for mitigating mitochondrial dysfunction and myotoxicity.Inflammation and regeneration · 2026Review
- A hierarchical risk assessment framework for head-to-head comparison of statin safety profiles in Chinese patients.Scientific reports · 2026Article
- Article
- Article
- Advances in Non-statin Lipid Therapies: A Narrative Review of Evolving Strategies for Cardiovascular Risk Reduction.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2026Review
- The Potential ofDrug design, development and therapy · 2026Review
- Engineered biodegradable polymeric nanoparticles injectable system of atorvastatin for improved therapeutic activity.Scientific reports · 2025Article
- Effect of genetic polymorphism of rosuvastatin transporter gene rs2231137 on its clinical efficacy and safety.Scientific reports · 2025Article
- Are statin side effects dependent on sex? A narrative review.Przeglad menopauzalny = Menopause review · 2025Review
- Trends in Reports of Statin-Associated Immune-Mediated Necrotizing Myopathy Using the Japanese Adverse Drug Event Report Database.Drugs - real world outcomes · 2025Article
- Article
- Article
- Statins in the Cause and Prevention of Cancer: Confounding by Indication and Mediation by Rhabdomyolysis and Phosphate Toxicity.Journal of cardiovascular development and disease · 2024Review
- Rosuvastatin-induced rhabdomyolysis: case report and call for proactive multifactorial risk assessment and preventive management of statin therapy in high-risk patients.European journal of hospital pharmacy : science and practice · 2024Article
- Severe Rhabdomyolysis Due to Presumed Drug Interactions of Dapagliflozin with Rosuvastatin: A Case Report.Indian journal of nephrologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The efficacy of statins in the primary and secondary prevention of cardiovascular disease has been proven beyond doubt. The number needed to treat to prevent one cardiovascular event is 1 in 30 over 10 years, and the number needed to treat for secondary prevention is much lower. However, a recent study demonstrated that only 68% of eligible patients are on statin therapy. Moreover, there seems to be a reluctance to escalate statin doses due to the fear of adverse effects. The adverse effects that worries patients and their physicians most frequently are those related to muscular symptoms. N-of-1 trial evidence suggests that muscular symptoms attributed to statins are often caused by the nocebo effect. This article aims to provide a structured, evidence-based approach to suspected statin-related muscle toxicity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.